Genes and environment: Nosology and psychiatry

Neurotoxicity Research

Volumn 6, Issue 1, 2004, Pages 11-15

  Klein, Donald F ^a   Stewart, Jonathan ^a  

^a New York State Psychiatric Institute ^*  (United States)

Author keywords

Ayptical depression; Hypothalamic pituitary adrenal axis; Monoamine oxidase inhibitor; Tricyclic antidepressant

Indexed keywords

ANTIDEPRESSANT AGENT;

DEPRESSION; ENVIRONMENT; GENETICS; HUMAN; REVIEW;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; ENVIRONMENT; HUMANS;

EID: 3242769284     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033292     Document Type: Article

References (24)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. (American Psychiatric Association, Washington, DC), 1994.
2. Asnis GM, LK McGinn and WC Sanderson (1995) Atypical depression: clinical aspects and noradrenergic function. Am. J. Psychiatry 152, 31-36.
3. Bielski RJ and RO Friedel (1976) Prediction of tricyclic antide-pressant response: A critical review. Arch. Gen. Psychiatry 33, 1479-1489.
4. Bruder GE, FM Quitkin, JW Stewart, C Martin, MM Voglmaier and WM Harrison (1989) Cerebral laterality and depression: Differences in perceptual asymmetry among diagnostic subtypes. J. Abnorm. Psychol. 98, 177-186. J
5. Holtzman NA and TM Marteau (2000) Will genetics revolutionize medicine? N. Engl. J. Med. 343, 141-144.
6. Hordern A (1965) The antidepressant drugs. N. Engl. J. Med. 272, 1159-1169.
7. Joyce PR and ES Paykel (1989) Predictors of drug response in depression. Arch. Gen. Psychiatry 46, 89-99.
8. Klein DF (1974) Endogenomorphic depression: A conceptual and terminological revision. Arch. Gen. Psychiatry 31, 447-451.
9. Klein DF (1989) The pharmacological validation of psychiatric diagnosis, In: Robins L and J Barrett (Eds.), Validity of Psychiatric Diagnosis (Raven Press, New York) pp 203-216.
10. Klein DF and J Davis (1968) Diagnosis and Drug Treatment of Psychiatric Disorders (Williams & Wilkins, Baltimore).
11. Liebowitz MR, FM Quitkin, JW Stewart, PJ McGrath, WM Harrison, JS Markowitz, JG Rabkin, E Tricamo, DM Goetz and DF Klein (1988) Antidepressant specificity in atypical depression. Arch. Gen. Psychiatry 45, 129-137.
12. McGinn LK, GM Asnis and E Rubinson (1996) Biological and clinical validation of atypical depression. Psychiatry Res. 60, 191-198.
13. Quitkin FM, JG Rabkin, JW Stewart, PJ McGrath, W Harrison, M Davies, R Goetz and J Puig Antich (1985) Sleep of atypical depressives. J. Affect. Disord. 8, 61-67.
14. Quitkin FM, JW Stewart, PJ McGrath, MR Liebowitz, WM Harrison, E Tricamo, DF Klein, JG Rabkin, JS Markowitz and SG Wager (1988) Phenelzine versus imipramine in the treatment of probable atypical depression: Defining syndrome boundaries of selective MAOI responders. Am. J. Psychiatry 145, 306-311.
15. Quitkin FM, PJ McGrath, JW Stewart, W Harrison, SG Wager, E Nunes, JG Rabkin, E Tricamo, J Markowitz and DF Klein (1989) Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression. Arch. Gen. Psychiatry 46, 787-93.
16. Quitkin FM, PJ McGrath, JW Stewart, W Harrison, E Tricamo, SG Wager, K Ocepek-Welikson, E Nunes, JG Rabkin and DF Klein (1990) Atypical depression, panic attacks, and response to imipramine and phenelzine: A replication. Arch. Gen. Psychiatry 47, 935-941.
17. Rabkin JG, JW Stewart, FM Quitkin, PJ McGrath, WM Harrison and DF Klein (1996) Should atypical depression be included in DSM-IV? In: Widiger TA, AJ Frances, HA Pincus, R Ross, MB First and WW Davis, DSM-IV Sourcebook, Vol. 2 (American Psychiatric Association, Washington, DC), pp 239-260.
18. Sargant W (1960) Some newer drugs in the treatment of depression and their relation to other somatic treatments. Psychosomatics 1, 14-17.
19. Stewart JW, PJ McGrath, JG Rabkin and FM Quitkin FM (1993) Atypical depression: A valid clinical entity? Psychiatr. Clin. North Am. 16, 479-495.
20. Stewart JW, FM Quitkin, PJ McGrath and GE Bruder (1999) Do tri-cyclic responders have different brain laterality? J. Abnorm. Psychol. 108, 707-710.
21. Stewart JW, PJ McGrath and FM Quitkin (2002) Do age of onset and course of illness predict different treatment outcome among DSM IV depressive disorders with atypical features? Neuropsychopharmacology 26, 237 245.
22. Stewart JW, GE Bruder, PJ McGrath and FM Quitkin (2003) Do age of onset and course of illness define biologically distinct groups within atypical depression? J. Abnorm. Psychol. 112, 253 262.
23. Van Praag HM (2002) Crossroads of corticotrophin releasing hormone, corticosteroids and monoamines. Neurotox. Res. 4, 531-555.
24. West ED and PJ Dally (1959) Effect of iproniazid in depressive syndromes. Br. Med. J. 1, 1491-1494.